NOVEL METHOD FOR PREVENTING OR TREATING MOTION SICKNESS
Technologies Available for License Standard Agreements Invention Disclosure Invention Agreement Dartmouth Policies Trademark Program Annual Reports Related Sites		Motion sickness has been a long-standing problem for travelers, aviators and sailors. For some people, motion sickness symptoms can ruin a trip or even be disabling. Common remedies taken to prevent symptoms often have undesirable side effects. Researchers at Dartmouth have discovered that the anti-histamine chlorpheniramine is effective in the prevention of motion sickness. Our studies demonstrated that chlorpheniramine increased the amount of stressful motion that subjects could tolerate in a rotating chair. The drug was well tolerated and did not affect performance on cognitive tasks. As expected from previous experience with the drug, subjects did report increased sleepiness after taking chlorpheniramine. Chlorpheniramine is an attractive drug for motion sickness treatment since it has an excellent safety record and is amenable to transdermal administration. Chlorpheniramine is used widely in over-the-counter allergy medications so it has an extensive track record. A transdermal preparation for relieving motion sickness offers several advantages including a) the potential to avoid side effects (such as sedation) due to peaks in drug concentration, b) long-lasting relief, and c) the ability to remove the preparation from the skin if side effects do occur. This use of chlorpheniramine and novel routes of its administration are claimed in the published United States Patent Application No. 10/786,429. We are seeking an industrial partner interested in its commercialization. (Ref: J217)

		«Technology Transfer Office : Sponsored Projects : Dartmouth College
11 Rope Ferry Road #6210			E-Mail: technology.transfer@dartmouth.edu
Hanover, NH 03755-1404			Phone: (603) 646-3027
			Fax: (603) 646-3670